BioCentury
ARTICLE | Clinical News

Ampligen: Began Phase IIb study

March 12, 2001 8:00 AM UTC

Hemispherx Biopharma Inc. (HEB), Philadelphia, Penn. Product: Ampligen Business: Infectious diseases Therapeutic category: Viral replication Target: 2-5A enzyme Description: Nucleic acid antiviral ag...